Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Among women with stage I HER2-positive breast cancer, adjuvant weekly paclitaxel plus
trastuzumab (PH, qw×12) is one of the standard therapies. However, it is quite inconvenient
for patients to received weekly treatment for 12 weeks, which also increased the patients'
and social economic burdens. In our study, a prospective, randomized, open-label,
single-center clinical study was conducted to compare the efficacy and safety of adjuvant
docetaxel plus trastuzumab (TH, q3w×4) and the classic regimen (PH, qw×12) in stage I
HER2-positive breast cancer in Chinese population.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University